Recap

Selecting Between CDK4/6 Inhibitors in Advanced HR+/HER2- Breast Cancer


 

Patients diagnosed with advanced hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–negative (HER2-) breast cancer have significantly improved outcomes with the combination of a cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy compared with endocrine therapy alone.

Dr Sara Hurvitz, director of the Breast Cancer Clinical Trials Program at UCLA, discusses the efficacy, tolerability, and patient quality-of-life factors to consider when deciding which of the three available CDK4/6 inhibitors — palbociclib, ribociclib, or abemaciclib — is appropriate for your patient in the frontline setting.

Reporting on data from the ongoing MONALEESA, MONARCH, and PALOMA trials, Dr Hurvitz spotlights the differences and similarities between agents that may help steer treatment decisions for pre- or perimenopausal patients

--

Associate Professor, David Geffen School of Medicine at UCLA; Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit; Co-director, Santa Monica-UCLA Outpatient Oncology Practices; Director, Breast Cancer Clinical Trials Program, UCLA, Los Angeles, California

Sara A. Hurvitz, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Ambrx; Amgen; Arvinas; Bayer; BioMarin; Cascadian Therapeutics; Daiichi Sankyo; Dignitana; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Immunomedics; Lilly; MacroGenics; Merrimack; Novartis; OBI Pharma; Pfizer; Phoenix Molecular Designs; Pieris; Puma Biotechnology; Radius; Samumed; Sanofi; Seattle Genetics; Zymeworks

Has been reimbursed for travel, accommodations, or other expenses by Lilly

Recommended Reading

Family history of breast cancer increases likelihood of dense breast in premenopausal women
MDedge Hematology and Oncology
Real-world evidence supports use of ribociclib+letrozole in males with HR-positive/HER2-negative BC
MDedge Hematology and Oncology
HER2-negative early BC: Subset of patients may benefit from anthracycline-containing chemotherapy
MDedge Hematology and Oncology
Pretreatment circulating reproductive hormones predict treatment response in breast cancer
MDedge Hematology and Oncology
Avoiding delay in AHT may improve survival in HR-positive, ERBB2-negative early BC
MDedge Hematology and Oncology
Breast density linked to familial breast cancer risk
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: Breast Cancer April 2022
MDedge Hematology and Oncology
False-positive breast cancer screening likely over 10-year period
MDedge Hematology and Oncology
Is this the most controversial issue in early breast cancer treatment?
MDedge Hematology and Oncology
Obesity increasing the risk for cancer: It’s complicated
MDedge Hematology and Oncology